Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-25-004349
Filing Date
2025-06-03
Accepted
2025-06-03 16:32:00
Documents
1
Period of Report
2025-05-30

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 5864
  Complete submission text file 0001562180-25-004349.txt   7479
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Issuer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O REGENXBIO INC. 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address
Glucksmann Alexandra (Reporting) CIK: 0001658390 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37553 | Film No.: 251020148